Floatz logo

Tafasitamab

Recurrent Diffuse Large B-Cell Lymphoma

The First Affiliated Hospital of Soochow Universitymonoclonal_antibodyPhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

107 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
DEXAMETHASONE
City of Hope Medical Center
Phase 2/3BB
Ifosfamide
University of California, Davis
Phase 3BB
Cyclophosphamide
Nathan Denlinger
Phase 3BB
ETOPOSIDE
University of California, Davis
Phase 3BB

View all 50 →

Same molecule, other indications

Tafasitamab is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
high grade B-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →